Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
California-based Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, has announced the closing of an $88.5 million Series B financing round. 19 July 2021
Pharmaceutical
Shares of US drugmaker AcelRx Pharmaceuticals shot up 23.8% to $1.51 yesterday, after the company announced agreements with French family-owned company Laboratoire Aguettant, providing the later with a license to commercialize Dzuveo (sufentanil) sublingual tablet in Europe, and providing AcelRx with two innovative pre-filled syringe product candidates for the USA. 15 July 2021
Biotechnology
Privately-held Irish company Shorla Pharma has announced its arrival in the USA by locating a base in Boston's Cambridge biotech cluster. 15 July 2021
Biotechnology
Ionis Pharmaceuticals has exercised its option and entered into an exclusive worldwide license and collaboration agreement with Bicycle Therapeutics for tissue-targeted delivery of oligonucleotide therapeutics. 13 July 2021
Biotechnology
Hutchmed says that the first commercial sale in China of Orpathys (savolitinib), the Chinese firm's oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, occurred on July 12, 2021. 13 July 2021
Biotechnology
Shares in New Jersey, USA-based Celldex Therapeutics leapt by a quarter on Monday, after the firm announced positive results from an ongoing Phase Ib trial of CDX-0159. 13 July 2021
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ASP3772 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years and older. 13 July 2021
Biotechnology
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience have announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, the Texas biotech’s VISTA antagonist antibody. 12 July 2021
Biotechnology
England’s health technology assessor, the National Institute for Health and Care Excellence (NICE), has dealt a blow to Orchard Therapeutics’ reimbursement goals for atidarsagene autotemcel. 12 July 2021
Biotechnology
Data from two Phase II studies investigating bemcentinib in hospitalized COVID-19 patients have been presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) by Norwegian biotech BerGenBio. 12 July 2021
Biotechnology
Belgian cell therapy company Bone Therapeutics, which is addressing unmet medical needs in orthopedics and other diseases, has appointed Anne Leselbaum as chief medical officer (CMO), effective August 23, 2021. 12 July 2021
Biotechnology
Shares of UK and USA-based clinical stage biotech F-star Therapeutics were up 11% at $8.15 pre-market, as it revealed it has entered into an exclusive licensing agreement with AstraZeneca,, under which the Anglo-Swedish pharma major will receive global rights to research, develop and commercialize next generation Stimulator of Interferon Genes (STING) inhibitor compounds. 8 July 2021
Biotechnology
New Jersey, USA-based Outlook Therapeutics has appointed C. Russell Trenary III as president and chief executive. 8 July 2021
Biotechnology
Boston, USA-based next-generation oncology company Scorpion Therapeutics says that Dr Axel Hoos will join the company as its new chief executive, effective August 2021. 8 July 2021
Biotechnology
Shares of Provention Bio (Nasdaq: PRVB) closed own more than 26% at $6.11 yesterday, after the US biotech revealed a regulatory setback for its diabetes drug. 7 July 2021
Biotechnology
Privately-held US biotech Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) have entered into a license agreement with French pharma major Sanofi for the non-CAR use of a novel, human binding domain targeting GPRC5D (G Protein-Coupled Receptor Family C Group 5 Member D). 7 July 2021
Biotechnology
USA-based Arbutus Biopharma and the UK’s Vaccitech have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus (HBV) infection (CHB) who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy. 6 July 2021
Biotechnology
French oncology-focused biotech Innate Pharma saw its shares fall more than 4% to 2.94 euros by midday, having dropped as much as 8%, after it said it would stop exploring its avdoralimab in COVID-19. 6 July 2021
Biotechnology
Austrian drug developer Marinomed Biotech today announced that Carragelose (Iota-/kappa-carrageenan)-based nasal sprays have been out-licensed for the Brazilian and Mexican markets. 6 July 2021
Biotechnology
Italian drugmaker Alfasigma has entered into an exclusive licensing agreement with USA-based cardiopulmonary diseases focused company PhaseBio Pharmaceuticals for the commercialization of bentracimab. 5 July 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze